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Background: Immunoglobulin-like transcript 4 (ILT4) is an inhibitory molecule involved in immune response and
has recently been identified to be strongly inducible by IL-10. The aim of the present study was to examine the
associations of ILT4 expression with clinicopathological characteristics and IL-10 expression in primary ductal and
lobular breast cancer.
Methods: We studied the expression of ILT4 in 4 cancer cell lines, 117 primary tumor tissues and 97 metastatic
lymph nodes from patients with primary ductal and lobular breast cancer by reverse transcription-polymerase chain
reaction, western blot or immunohistochemistry analysis. Additionally, IL-10 expression was also investigated using
immunohistochemistry in primary tumor tissues. Then the relationship between ILT4 expression and clinicopathological
characteristics/IL-10 expression was evaluated.
Results: ILT4 was highly expressed in all 4 human breast cancer cell lines on both mRNA and protein levels. In primary
tumor tissues, ILT4 or IL-10 was expressed in the cell membrane, cytoplasm, or both; the positive rate of ILT4 and IL-10
expression was 60.7% (71/117) and 80.34% (94/117), respectively. ILT4 level was significantly correlated with IL-10
(r =0.577; p < 0.01). Furthermore, the expression of ILT4 or IL-10 was associated with less number of Tumor Infiltrating
Lymphocytes (TILs) (p = 0.004 and 0.018, respectively) and more lymph node metastasis (p = 0.046 and 0.035,
respectively).
Conclusion: Our data demonstrated the association of ILT4 and IL-10 expression in human breast cancer, suggesting
their important roles in immune dysfunction and lymph node metastases.
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Breast cancer is one of the most common female malig-
nancies in many countries [1]. Multidisciplinary ap-
proaches, including surgery, conventional chemotherapy,
radiotherapy, endocrine therapy, bisphosphonates, and
HER-2/neu directed therapy, have been used widely for
the patients’ treatment; however, a large number of pa-
tients responds poorly to these approaches. It is import-
ant to expand repertoire of new molecular markers for
further therapeutic strategies.
Effective immune response involving T-cell activation
defenses normal cells against pathogens through produ-
cing cytokines or cytotoxicity. However, immune response
to tumor cells is usually inadequate or inactivated, which
is one of the most common reasons caused tumor growth,
invasion and metastasis [2,3]. Co-stimulatory molecules
expressed by antigen presenting cells or tumor cells play a
large role in T-cell activation: stimulatory molecules acti-
vated T-cell response, and inhibitory molecules suppressed
it. When lacking stimulatory molecules (CD80 and CD86)
expression or over-expressing inhibitory molecules (B7-
H1, B7-H3 and B7-H4) in tumor cells, T-cell is induced to
be tolerant or anergic [4,5], which is considered to be
associated with immune response escape during cancer
development [6-9]. Therefore, studies of co-stimulatory
molecules in tumors are not only critical for understand-
ing mechanisms involving in tumor associated immune
response, but also helpful for finding new targets of tumor
therapy.
Immunoglobulin-like transcripts (ILTs; also referred to
as leukocyte immunoglobulin-like receptors) represent a
novel immunoglobulin superfamily of both inhibitory and
stimulatory receptors involved in immune surveillance
[10-12], and are closely related to the killer-cell inhibitory
receptor family mapping to the leukocyte receptor com-
plex [13-15]. ILT4, expressed by monocytes, dendritic cells
(DCs) and endothelial cells (ECs), has a long cytoplasmic
tail containing immunoreceptor tyrosine-based inhibitory
motifs which mediates inhibition of cell activation by
recruiting tyrosine phosphatase SHP-1 [12,16]. Upregula-
tion of ILT4 on professional and non-professional antigen-
presenting cells (APCs) can induce CD4+ T-helper cells
anergy; decrease stimulatory molecules expression in T
cells [17-19]; and elicit the differentiation of Ag-specific
CD4+ and CD8 +Treg cells [20]. In general, the biological
function of ILT4 is considered to inhibit the immune
response.
The expression of ILTs in cancer cells and their import-
ant role in tumor progression become more and more at-
tractive these days. ILT4 is found to be expressed in
NSCLC cells [21] with less number of Tumor Infiltrating
Lymphocytes (TILs) infiltrated; and the expression of ILT3
or ILT4 in neoplastic B cells is associated with lymphoid
tissue involvement in chronic lymphocytic leukemia [22].However, little is known about the expression and func-
tion of ILT4 in other human carcinomas, such as, breast
cancers.
IL-10, a pleiotropic cytokine, primarily produced by
Th2 cells and Treg cells, has been reported to induce
ILT4 upregulation in monocytes and DCs, rendering
them tolerogenic [23,24]. Furthermore, in human endo-
thelial cells (ECs), IL-10 also upregulates ILT3/ILT4 ex-
pression; and suppresses T-cell co-stimulatory potential
of human ECs [25]. However, there is no study to deter-
minate the relationship between ILT4 and IL-10 expres-
sion in tumor tissues and assay their role in tumor
progression. We here aimed to evaluate the immunohis-
tochemistry expression of ILT4 and IL-10 in a series of
invasive ductal and lobular breast carcinomas; analyze
the association between ILT4 and IL-10 expression; and
discuss their role in breast cancer development through
assaying the relationship between ILT4/IL-10 expression
and prognostic factors. We hope our findings may be
the preliminary experiment for further study on IL-10
and ILT4 function in human breast cancer.
Materials and methods
Patient samples
Primary breast cancer specimens were obtained from
117 patients without any preoperative therapy who
underwent surgery at Jinan Central Hospital Affiliated to
Shandong University, China, between Dec 1st, 2008 and
Dec 30th, 2010. All patients signed the informed consent
for use of specimens, and the study was approved by the
Institutional Review Board (Medical Ethics Committee
of Jinan Central Hospital). The median age of patients
was 51 years (range, 21 ~ 77 years) at the time of diagno-
sis. These specimens were 97 invasive ductal carcinomas
and 20 lobular carcinomas. Cases with mixed patterns of
histologic differentiation were excluded from the ana-
lysis. The study also included 97 tumor metastatic lymph
nodes from a subset of 12 patients who were from the
study group. The tumors were classified as pathologic
stage I (33 cases), stage II (52 cases), and stage III (32
cases) using American Joint Committee criterions.
Cell lines
Human breast cancer cell lines MDA-MB-453, MCF-7,
SK-BR-3 and MDA-MB-231 were used in cell experi-
ments. SK-BR-3 and MDA-MB-231 cells were purchased
from Cell Resource Center, the Institute of Basic Medical
Sciences Chinese Academy of Medical Sciences (Beijing,
China). MDA-MB-453 and MCF-7 were conserved in our
laboratory. These cell lines were cultured at 37°C in a hu-
midified atmosphere of 5% CO2 in Roswell Park Memorial
Institute (RPMI) 1640 medium (Invitrogen, California,
USA) supplemented with 10% fetal bovine serum (Invitro-
gen, California, USA).
Figure 1 ILT4 expression in human breast cancer cell lines.
A: ILT4 mRNA expression was assayed by RT-PCR in breast cancer
cell lines. A representative result from 3 independent experiments
was shown. B: ILT4 protein expression was determined by Western
blot analysis. A representative result from 3 independent
experiments was shown. β-actin was used as the control.
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Cancer cells were harvested and lysed in total RNA isola-
tion Reagent (RNAiso plus, TaKaRa Biotech, Dalian,
China). First-strand cDNAs were prepared with random
primers following the instructions of the kit (RNA PCR
KIT (AMV) v3.0, TaKaRa Biotech, Dalian, China). RT-PCR
involved the primers for human ILT4 5′GGAGCCTACC
CAAAACCC (forward), 5′ GTGCGACCACCTGCGATT
(reverse) with use of hot-start Taqgold enzyme (Roche
Diagnostic GmbH, Penzberg, Germany). Expression was
normalized by β-actin with primers 5′ GGGACCTGACT
GACTACCTC (forward), 5′ TCATACTCCTGCTTGCT
GAT (reverse). Cycle conditions were: 94°C, 2 min;
42 cycles for 94°C, 30s; 62°C, 30s; and 72°C, 30s.
Western blot analysis
Total proteins were extracted from breast cancer cell
lines (MDA-MB-453, MDA-MB-231, MCF-7 and SK-BR-
3) using RIPA Lysis Buffer (Beyotime, Jiangsu, China) and
separated by SDS-PAGE (10%) (Beyotime, Jiangsu, China).
These proteins were transferred to 0.45 μm polyvinylidene
difluoride membrane (Millipore, Massachusetts, USA)
by Bio-Rad transference chamber (Bio-Rad Laboratories,
California, USA). Primary antibody to ILT4 (R & D,
Minneapolis, USA; dilution 1:500) was used to detect the
protein expression. The membrane was incubated with
appropriate secondary antibodies labeled to horseradish
peroxidase (Santa cruz, California, USA; dilution 1:5000).
The protein levels were normalized by reprobing the blots
with antibody to β-actin (Santa cruz, California, USA; di-
lution 1:1000). The signals were detected by the ECL Plus
Western Detection Kit (Beyotime, Jiangsu, China) and re-
corded on the Kodak X-ray films. The protein expression
was determined utilizing the BandScan 5.0 software.
Immunohistochemistry
Immunohistochemical staining was performed as described
in our previous studies [9,21]. Briefly, anti-ILT4 mouse
monoclonal antibody (R & D, Minneapolis, USA; dilution
1:400), anti-IL-10 mouse monoclonal antibody (Abcam,
Massachusetts, USA; dilution 1:100) and anti-CD45RO
mouse monoclonal antibody (Abcam, Massachusetts, USA;
dilution 1:100) were used as the primary antibodies. Nor-
mal mouse IgG was provided as negative control.
Assessment of Immunohistochemical staining
Immunohistochemical analysis was performed by two
independent investigators simultaneously. The percent-
age of stained cells was recorded at ×400 magnification,
in at least 5 random fields. ILT4 and IL-10 expression
were evaluated based on the percentage of positive-
staining tumor cells [21]. More than 10% of ILT4 brown
staining cells was considered as positive while negative
(expression <10%). IL-10 expression was divided intohigh and low group with focal staining intensity more or
less than 40%. For studying the relationships between
ILT4 and TILs, we counted the number of CD45RO +
cells per 1000 total nuclei as described previously [26].
Information on ER, PR, and HER-2/neu status was ob-
tained from the original surgical pathological reports. ER
and PR positive staining was defined as staining of >10%
of cells. HER-2/neu positivity was defined as 3+ on
staining (>30% positive staining of invasive cancer cells)
or was determined by fluorescence in situ hybridization
(Vysis, Downers Grove, USA) at Quest Diagnostics.
Statistical analysis
The association of ILT4 or IL-10 expression and clinico-
pathological variables was analyzed by Chi-square test.
The correlation between TILs cell number and ILT4/IL-
10 expression was compared by Student’s t test. With
Spearman correlation coefficient, the relationship of ex-
pression between ILT4 and IL-10 was evaluated. p < 0.05
was considered to be statistically significant. Statistical
analysis was performed using SPSS v15.0 (SPSS Inc.,
Chicago, USA).
Results
ILT4 expression in human breast cancer cell lines
ILT4 expression in all of the 4 human breast cancer cell
lines was found at both mRNA and protein levels by RT-
PCR (Figure 1A) and Western blot analysis (Figure 1B),
respectively.
ILT4 and IL-10 expression in human breast cancer tissues
The expression of ILT4 and IL-10 in 117 primary tumor
specimens was determined by immunohistochemistry.
Both ILT4 and IL-10 positive expression were identified in
tumor cell cytoplasm, membrane, or both (Figure 2A-B).
In normal breast tissues, their expression was absent
(Figure 2C-D). Of 117 specimens, the positive rate of
Figure 2 Immunohistochemical analysis of ILT4 and IL-10 expression in sections from primary breast cancer (200×). A: ILT4 positive
expression in invasive ductal breast cancer. B: IL-10 positive expression in invasive ductal breast cancer. C: ILT4 expression was absent in adjacent
normal breast tissues. D: IL-10 expression in adjacent normal breast tissues was also negative. E: ILT4 positive tumor cells in metastatic
lymph nodes.
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(94/117), respectively. Expression of ILT4 was also seen in
some stromal macrophages, fibroblasts and plasma cells,
and expression of IL-10 was also observed in infiltrating
lymphocytes in accordance with previous studies [21,27]
(Data was not shown). Furthermore, the expression of
ILT4 and IL-10 showed a significant correlation (r = 0.577,
p < 0.01; Figure 3A).
ILT4 expression in lymph node metastasis
In metastatic lymph nodes, the positive rate of ILT4 ex-
pression was 74.2% (72/97) which derived from 12 pa-
tients (Figure 2E); and the staining intensity which
indicated the expression level was always identical
among individual lymph nodes from the same patient.
Furthermore, the localization and expression level ofILT4 in tumor cells was similar between primary tu-
mors and corresponding nodal metastasis. Within ILT4-
negative tumor metastatic lymph nodes (n = 25), almost
all corresponding primary tumors showed negative ILT4
expression except one with 10%-40% ILT4 expression rate
in primary tumor.
Correlation of ILT4/IL-10 expression with the number of
TILs
We next assessed the relationship between the expres-
sion of ILT4 or IL-10 and the number of TILs in all
tumor specimens. Compared to ILT4 or IL-10 negative
expression tissues, the amount of TILs seemed to be less
in ILT4 or IL-10 positive tissues. The mean number of
TILs in ILT4-positive group was 26.71 ± 11.85 and was
significantly lower than that in the ILT4-negative group,
Figure 3 Association between ILT4, IL-10 expression and number of TILs in breast cancer tissues. A: Correlation between ILT4 and IL-10
expression in breast cancer (r = 0.577, p < 0.01). B: The number of CD45RO + TILs was significantly less in ILT4 positive breast cancer tissues than
that of negative group (26.71 ± 11.85 and 33.58 ± 13.73, respectively; p = 0.004). C: The number of CD45RO + TILs also decreased in IL-10 positive
breast cancer tissues compared to negative group (27.65 ± 12.91 and 34.80 ± 14.49, respectively; p = 0.018).
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mean TILs number in IL-10-positive group was 27.65 ±
12.91, whereas 34.80 ± 14.49 TILs in IL-10-negative
group (p = 0.018; Figure 3C).
Relationship of ILT4/IL-10 expression with clinical
characteristics of breast cancer
As shown in Table 1, expression level of ILT4 or IL-10
was much higher in cases with lymph node metastasis
(p = 0.046 and 0.035, respectively). Patients with high ex-
pression level of IL-10 were more likely to have ad-
vanced disease (stage II-III; p = 0.039) compared to thosewith IL-10 low expressed. However, no significant cor-
relation was identified between ILT4 expression and
tumor stage. Both of ILT4 and IL-10 expressions have
no relation with other clinicopathological factors (age,
histologic types, grade, tumor size, stages, or receptor
status).
Discussion
Cancer is a heterogeneous disease consisting of multiple
subgroups with different molecular signatures and clin-
ical behaviors [28,29]. The heterogeneity of breast cancer
includes differences in ethnicity, menopausal status, ER/







Positive Negative High Low
Age
≤50 63 40 23 0.502 34 29 0.854
>50 54 31 23 28 26
Histologic Types
ductal cancer 97 60 37 0.568 53 44 0.432
lobular cancer 20 11 9 9 11
Grade
I-II 22 10 12 0.105 10 12 0.483
III 95 61 34 52 43
Tumor size
≤2 cm 50 27 23 0.201 21 29 0.061
>2 cm 67 44 23 41 26
Lymph node metastasis
N0 43 21 22 0.046 17 26 0.035
N1-3 74 50 24 45 29
TNM stage
I 33 16 17 0.09 12 21 0.039
II-III 84 55 29 50 34
ER
positive 82 50 32 0.921 40 42 0.225
negative 35 21 14 22 13
PR
positive 78 47 31 0.894 38 40 0.239
negative 39 24 15 24 15
HER2
positive 30 17 13 0.601 11 19 0.055
negative 87 54 33 51 36
Note: “Bolded values” refer to the statistically significant data.
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signatures [30,31]. Finding the sources of breast cancer
heterogeneity would contribute to subtype specific the-
rapeutic approaches. ILT4, belonging to the family of
immunoglobulin-like inhibitory receptors, plays important
roles in modulating the allo-specific antigen immune re-
sponse to transplants [32]; inducing immune tolerance in
pregnancy [33]; and inhibiting myeloid dendritic cell func-
tion in HIV-1 infection [34]. And IL-10 is found to regu-
late the expression of ILT4 in monocytes, DCs and human
ECs [24,25]. Besides, emerging evidences suggest that the
aberrant expression of ILT4 is involved in tumor progres-
sion and lymph node metastasis [21,22]. However, the ex-
pression and function of ILT4 in breast cancer and the
relationship between ILT4 and IL-10 expression in cancer
cells are poorly understood.In our present study, ILT4 was found to be highly
expressed in human breast cancer cell lines, primary tis-
sue specimens and metastatic lymph nodes, while no
ILT4 expression was detected in normal breast tissues. It
was also expressed in a few macrophages, fibroblasts
and plasma cells in breast cancer tissues, which was con-
sistent with the expression pattern in NSCLC tissues
[21]. In addition, expression of ILT4 was significantly
correlated with lymph node metastasis in clinical breast
cancer samples. Previous reports have shown that ILT4
plays an essential role in inducing T-cell anergy, and is
necessary for eliciting the differentiation of Ag-specific
CD4+ and CD8 + Treg cells [12,17,23]. Furthermore,
some studies also revealed that ILT4 was frequently
expressed in NSCLC and malignant B cells [21,22], sug-
gesting its important role in tumor cells. Consistent with
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of breast cancer tissues overexpressing ILT4. ILT4
expressed in tumor cells may act as an inhibitory
molecule to suppress the T-cell activity, induce T help
cells anergy, or inhibit the differentionation of cytotoxic
T cells in microenvironment. It might assist tumor cells
in escaping from immune surveillance and facilitate the
invasion of tumor cells in lymph nodes. Further studies
on detailed mechanisms underlying ILT4 role in human
breast cancer warrant further investigation.
Our study further demonstrated that ILT4 overexpres-
sion in breast cancer was associated with the overexpres-
sion of IL-10. IL-10, a cytokine synthesis inhibitory factor,
inhibits T cell or macrophage cytokine synthesis and sup-
presses their antigen-presenting capacity [35-37]; and was
reported to stimulate ILT4 expression through enhancing
its promoter activity in human monocytic leukemic cell
line THP-1 [24]. IL-10 overexpression in breast cancer
confers tumor growth and aggressiveness [38], and is con-
sidered as a prognostic indicator for breast cancer [39]. In
this study, we found IL-10 expression was not only associ-
ated with advanced stage and lymph node metastasis in
human primary breast cancer tissues, but also significantly
correlated with ILT4 expression (r = 0.577; p < 0.01). Inter-
estingly, the number of CD45RO +TILs in ILT4 or IL-10
positive cancer tissues was less than that of negative
groups. CD4 +CD45RO+CD25 + T-cells have been re-
ported to be anergized when IL-10 induces ILT3 and ILT4
upregulation in DCs [23]. We postulated that IL-10 may
at least partially regulate the expression of ILT4 in human
breast cancer cells; the expression of ILT4 and IL-10 might
promote tumor growth and progression by inhibiting the
proliferation of CD45RO +TILs and inducing the apop-
tosis of CD45RO+TILs in the tumor environment. ILT4
and IL-10 may be cooperatively used as predictors of clin-
ical outcomes in breast cancer patients.
In summary, ILT4 was found to be highly expressed in
primary human ductal and lobular breast cancer cells, and
its expression was significantly correlated with more IL-10
expression, less TILs amount and further lymph node me-
tastasis. Based on previous work and our findings presented
here, ILT4 expression in breast cancer may be regulated by
IL-10 and promote lymph node metastasis by inducing
TILs apoptosis and suppressing T-cell response. However,
whether IL-10 upregulated ILT-4 expression through en-
hancing its promoter activity, and what underlying
mechanism of ILT4 and IL-10 act in breast cancer warrant
further exploration. Nevertheless, this is the first time to de-
scribe the expression of ILT4 and IL-10 in solid tumor cells
and analyze the correlation between them. ILT4 may pro-
vide a promising target for breast cancer targeted therapy.Competing interests
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